Mipomersen, developed by Isis Pharmaceuticals and marketed by Genzyme, is an antisense oligonucleotide that targets the apolipoprotein B-100 (ApoB-100) mRNA.

Brentuximab Vedotin, also known as Adcetris, is an antibody-drug conjugate (ADC) developed by Seattle Genetics and Takeda Pharmaceutical Company.

Imetelstat is a first-in-class telomerase inhibitor developed by Geron Corporation, targeting the enzyme telomerase.

ADO-Trastuzumab Emtansine, also known as Kadcyla, is an antibody-drug conjugate (ADC) developed by Genentech, a member of the Roche Group.

Fomivirsen, developed by Isis Pharmaceuticals, is an antisense oligonucleotide that targets the messenger RNA (mRNA) of cytomegalovirus (CMV).

Eculizumab is a humanized monoclonal antibody that targets the complement protein C5. Developed by Alexion Pharmaceuticals.

Eteplirsen, developed by Sarepta Therapeutics, is an antisense oligonucleotide that targets the dystrophin gene.

Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR).

Eplontersen, is an antisense oligonucleotide developed by Ionis Pharmaceuticals and Akcea Therapeutics.

Basiliximab is a chimeric monoclonal antibody that targets the interleukin-2 receptor (IL-2R) alpha chain, also known as CD25.

Casimersen, developed by Sarepta Therapeutics, is an antisense oligonucleotide (AON) designed to target and skip exon 45 of the dystrophin gene.

Avastin, also known as bevacizumab, is a monoclonal antibody developed by Genentech, a subsidiary of Roche.